Krystal Biotech的股票尽管缺少收入估计数,价值211.13美元,却仍得到“Buy”评级。 Krystal Biotech's stock receives a "Buy" rating despite missing earnings estimates, valued at $211.13.

Krystal Biotech(Krystal Biotech)是一家开发稀有疾病的遗传药物的生物技术公司,其库存被分析师评为“Buy”,目标价格为211.13美元。 Krystal Biotech, a biotech firm developing genetic medicines for rare diseases, has seen its stock rated as "Buy" by analysts with a target price of $211.13. 尽管在其最新报告中缺少收入和收入估计数,公司股票的市场上限为40.1亿美元,物价与收益比率为33.38。 Despite missing earnings and revenue estimates in its latest report, the company's stock has a market cap of $4.01 billion and a price-to-earnings ratio of 33.38. 伊利诺伊州市政退休基金最近减少了其在该公司的股份。 Illinois Municipal Retirement Fund recently reduced its holdings in the company.